已在美国纳斯达克、港交所双重上市的医药公司百济神州正在申请科创板上市。方达律师事务所担任发行人律师;君合律师事务所则为联席保荐人提供法律意见。

百济神州成立于2010年,总部位于北京,主要从事用于治疗癌症的创新分子靶向及免疫肿瘤药物的研发、生产和销售业务。2016年,百济神州在美国纳斯达克上市,并于2018年登陆港交所,成为首个在美股和港股双重上市的中国生物医药公司。若此次科创板上市成功,百济神州将成为首支三重上市的生物医药股。

据招股书显示,方达团队的经办律师为合伙人丁继栋、刘一苇、方媛;君合团队的经办律师为合伙人余永强、陶旭东。

此次科创板上市项目的联席保荐人为中金公司、高盛。

 

Fangda, JunHe on dual listed biomedicine maker’s application for Shanghai’s STAR Market triple listing

Fangda Partners is advising BeiGene, a Chinese biopharmaceutical company listed in Nasdaq and HKEx, on its planned listing in Shanghai Stock Exchange’s STAR Market, with JunHe advising the joint sponsors.

Established in 2010, the Beijing-headquartered BeiGene focuses on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. BeiGene launched its IPO in Nasdaq in 2016 and was later listed in Hong Kong in 2018, becoming the first US and HK dual listed Chinese biopharmaceutical company. If successfully listed in STAR Market, the company will become the first of its kind to be triple listed.

According to the prospectus, the Fangda team is led by partners Ding Jidong, Liu Yiwei and Fang Yuan, and the JunHe team is led by partners Yu Yongqiang and Tao Xudong.

The joint sponsors are CICC and Goldman Sachs.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.